What is the efficacy of rituximab in the treatment of extraglandular symptoms of Sjögren syndrome?

Updated: Mar 05, 2021
  • Author: Sriya K Ranatunga, MD, MPH; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Rituximab appears promising in the treatment of vasculitis and intravenous immunoglobulin (IVIG)–dependent ataxic neuropathy. [83, 84] Results from the AIR registry (French) indicated that rituximab appears to be effective in cryoglobulinemia or vasculitis-related peripheral nervous system involvement in primary Sjögren syndrome. [85]

In a prospective study of 78 patients with primary Sjögren syndrome treated with rituximab, significant improvement in extraglandular manifestations was reported, as measured by EULAR [European League Against Rheumatism] Sjögren Syndrome Disease Activity Index (ESSDAI) (disease activity score) and overall good tolerance reported. [86] Several smaller studies of rituximab revealed improvement of arthralgias, regression of parotid gland swelling, [87] and improvement of immune-related thrombocytopenia. [88]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!